Ribavirin inhibits protein synthesis and cell proliferation induced by mitogenic factors in primary human and rat hepatocytes

被引:25
作者
Ilyin, GP [1 ]
Langouët, S
Rissel, M
Delcros, JG
Guillouzo, A
Guguen-Guillouzo, C
机构
[1] Hop Pontchaillou, INSERM U49, Unite Rech Hepatol, F-35033 Rennes, France
[2] Fac Sci Pharmaceut & Biol, INSERM U456, Rennes, France
[3] Fac Med, CNRS URA 1529, Rennes, France
关键词
D O I
10.1002/hep.510270630
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Ribavirin, a guanosine analog, used in combination with interferon alpha (IFN-alpha) in the treatment of chronic hepatitis induced by hepatitis C virus (HCV) infection, has been shown to improve liver histology and to decrease transaminases even when administered alone. We analyzed the direct effects of ribavirin on the liver by using primary cultures of human and rat hepatocytes. Between 10 to 60 mu mol/L, ribavirin was found to inhibit both the synthesis and secretion of whole proteins in a time- and dose-dependent fashion. Such an effect was confirmed by the measurement of albumin and haptoglobin secretion rates. [H-3]-Thymidine incorporation was suppressed both in hepatocyte growth factor-stimulated human hepatocytes and in epidermal growth factor (EGF)-stimulated rat hepatocytes in the presence of ribavirin, The inhibitory effect on DNA synthesis was associated with a delayed progression to S phase of the cell cycle, as determined by flow cytometry and detection of cyclin A and cdc2 which are two proteins expressed during the S phase. The inhibition of DNA synthesis, caused by 50 mu mol/L ribavirin, was completely restored by the addition of 80 mu mol/L guanosine. These observations demonstrate that ribavirin at concentrations close to those found in plasma of treated patients can directly affect hepatic functions in vitro. Its effects could, however, be reduced in vivo by guanosine salvage supply.
引用
收藏
页码:1687 / 1694
页数:8
相关论文
共 35 条
  • [21] IL-3 AND RIBAVIRIN INDUCE DIFFERENTIATION AND GROWTH SUPPRESSION DURING LONG-TERM TREATMENT OF A MEGAKARYOCYTIC LEUKEMIA-CELL LINE
    MAJUMDAR, A
    KERBY, S
    MULLIKIN, B
    BECKSTEAD, JH
    STENBERG, PE
    SEIDMAN, MM
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 1995, 165 (03) : 530 - 537
  • [22] Ning Q., 1996, Hepatology, V24, p355A
  • [23] PEAVY DL, 1980, INFECT IMMUN, V29, P583
  • [24] CLONING OF P27(KIP1), A CYCLIN-DEPENDENT KINASE INHIBITOR AND A POTENTIAL MEDIATOR OF EXTRACELLULAR ANTIMITOGENIC SIGNALS
    POLYAK, K
    LEE, MH
    ERDJUMENTBROMAGE, H
    KOFF, A
    ROBERTS, JM
    TEMPST, P
    MASSAGUE, J
    [J]. CELL, 1994, 78 (01) : 59 - 66
  • [25] RIBAVIRIN PHARMACODYNAMICS IN HIGH-RISK PATIENTS FOR ACQUIRED-IMMUNODEFICIENCY-SYNDROME
    ROBERTS, RB
    LASKIN, OL
    LAURENCE, J
    SCAVUZZO, D
    MURRAY, HW
    KIM, YT
    CONNOR, JD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (04) : 365 - 373
  • [26] A practical guide to the use of interferons in the management of hepatitis virus infections
    Saracco, G
    Rizzetto, M
    [J]. DRUGS, 1997, 53 (01) : 74 - 85
  • [27] Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C - Meta-analysis of individual patient data from European centers
    Schalm, SW
    Hansen, BE
    Chemello, L
    Bellobuono, A
    Brouwer, JT
    Weiland, O
    Cavalletto, L
    Schvarcz, R
    Ideo, G
    Alberti, A
    [J]. JOURNAL OF HEPATOLOGY, 1997, 26 (05) : 961 - 966
  • [28] COMBINED TREATMENT WITH INTERFERON-ALPHA-2B AND RIBAVIRIN FOR CHRONIC HEPATITIS-C IN PATIENTS WITH A PREVIOUS NONRESPONSE OR NONSUSTAINED RESPONSE TO INTERFERON ALONE
    SCHVARCZ, R
    YUN, ZB
    SONNERBORG, A
    WEILAND, O
    [J]. JOURNAL OF MEDICAL VIROLOGY, 1995, 46 (01) : 43 - 47
  • [29] SHULMAN NR, 1984, CLIN APPLICATIONS RI, P79
  • [30] SIDWELL R, 1972, SCIENCE, V117, P705